The World Health Organization (WHO) has declared a global diabetes epidemic and predicts there will be 592 million diabetics by the year 2035. 80% of diabetic patients will eventually develop some stage of Diabetic Retinopathy (DR), a severely under diagnosed complication that can lead to partial or total blindness. DR is the 5th leading cause of blindness, but if detected early, it CAN be treated.
Other retinal conditions on the rise include hypertensive retinopathy, macular degeneration and glaucoma, primarily driven by the aging global population. By providing a new easy to use, low-cost method to screen millions of people for retinal disease, more patients will be identified that require a follow up exam by an eye care professional driving demand for procedures to correct the identified problem, boost sales of associated products, and save the eyesight of potentially millions of people around the world.
Newborn and infant screening
15+ million newborns per year globally are premature and at risk of retinopathy of prematurity (ROP). There is no practical way to routinely examine newborns and infants for these abnormalities. In many cases, the earlier the retinal issues can be detected, the earlier corrective treatment can be instituted resulting in a better chance for a successful outcome.
Optibrand anticipates that newborn eye health screening could become a mandated standard of care in many markets.
The ability for the RetCheck® Technology to be placed on a smartphone opens up possibilities of large-scale screening of newborns. The software automatically captures the best images of the retina and does not require a patient to respond to directional commands.
Multiple enhancements to our software could be added to increase value on many devices. Artificial Intelligence and Deep Learning combined with RetCheck® would provide assistance in overcoming barriers to reach more patients and provide regular screening checkups worldwide.
Advances in mobile hardware and OS support for machine and deep learning are enabling smartphones to run stronger forms of AI for offline medical imaging solutions. The cost and size of mobile-ready handheld retinal imaging equipment is gradually declining while image quality is improving. These developments are opening up new possibilities for running detection and grading algorithms to provide an immediate outcome.
Our RetCheck® software can be adapted to perform with a variety of devices to automatically capture, select and give the most precise and reliable biometric match, aside from DNA, through matching of the retinal vasculature patterns. This type of system is easy to use, low cost, and portable.
Retinal imaging as a human identification biomarker is considerably more resistant to fraud when compared to iris, fingerprint, and facial recognition identification systems because it utilizes a biomarker that cannot be passively acquired without the subject’s knowledge and should be considered as part of any complete security solution offering